<table>
<thead>
<tr>
<th>Trial Name</th>
<th>Protocol #</th>
<th>PI</th>
<th>Study Contact</th>
<th>Key Eligibility &amp; Screening</th>
<th>Treatment Arms</th>
</tr>
</thead>
</table>
| Neoadjuvant Pembro for Stage II Melanoma | UPCC 09618 | Giorgos Karakousis | CRC: Alex Mathew, CRNs: Jennifer Tabita-Martinez & Lydia Giles | Clinical stage III/B/C resectable melanoma  
Uveal or mucosal melanoma not eligible  
No other active malignancy except treated cutaneous SCC, BCC or carcinoma in situ  
No active autoimmune disease requiring systemic treatment in prior 3 months | 1 dose pembro + WLE/SLNBx + pembro 1 yr  
Arm A: If Path CR/NEarCR, then 1 yr adjuvant nivo  
Arm B: If Path CR/NEarCR, then 1 yr adjuvant nivo  
Arm C: If Path CR/NEarCR, then 1 yr adjuvant ipi/nivo x 4 + nivio 1 yr |
| Neoadjuvant Nivo for Stage III Melanoma | UPCC 02619 | Tara Mitchell | CRC: Shraya Divaker, CRNs: Jennifer Tabita-Martinez, Lydia Giles | Clinical stage III resectable melanoma  
Uveal or mucosal melanoma not eligible  
No other active malignancy except treated cutaneous SCC, BCC or carcinoma in situ  
No active autoimmune disease requiring systemic treatment in prior 3 months | 1 dose nivo + definitive 5x + randomized into arm after pathological response known  
Arm A: If Path CR/NEarCR, then 1 yr adjuvant nivo  
Arm B: If Path CR/NEarCR, then 1 yr adjuvant nivo  
Arm C: If Path CR/NEarCR, then 1 yr adjuvant ipi/nivo x 4 + nivio 1 yr |
| Neoadjuvant Pembro for MCC | UPCC 01622 | John Miura    | CRC: Alex Mathew, CRNs: Jennifer Tabita-Martinez, Lydia Giles | Clinical stage I-II MCC  
Must have adequate tumor burden to yield 2-4 pre-operative research bx  
Non-cutaneous SCC not eligible  
No active CNS metastases and/or carcinomatous meningitis; Brain MRI needed | 1 dose of pembro + definitive 5x + adjuvant pembro  
Arm A: adjuvant cemiplimab up to 48 wks  
Arm B: placebo |
| Adjuvant Cemiplimab for SCC | UPCC 04619 | Joanna Walker | CRC: Sheridan Schwartz, CRN: Mollie Diehl | Pathologic resected CSCC: primary lesion, primary with nodal involvement, or nodal metastasis with known primary  
Completion of curative intent post-op RT within 2-6 wks of randomization  
Non-cutaneous SCC not eligible  
No other concurrent malignancy other than localized CSCC within 3 yrs of randomization  
No hematologic malignancies  
No history of distant metastatic CSCC  
No autoimmune diseases  
No prior systemic anti-cancer immunotherapy for CSCC | Arm A: ipi/Nivo  
Arm B: placebo |
| RadVax for Metastatic Melanoma | UPCC 0618  | Tara Mitchell | CRC: Alex Mathew, CRNs: Jennifer Tabita-Martinez, Lydia Giles | Histologically confirmed metastatic melanoma (includes CNS mets)  
≥ 2 measurable lesions per RECIST 1.1  
HFRT index lesion 1.7 cm  
Prior adjuvant anti-PD-1 allowed (4 wk washout)  
Prior therapy with CTLA-4 allowed  
CNS mets – symptomatic or require urgent local therapy are excluded | Arm A: ipi/Nivo  
Arm B: ipi/Nivo + radiation |
| Merck Umbrella for Metastatic Melanoma | UPCC 03621 | Tara Mitchell | CRC: Shraya Divaker, CRNs: Jennifer Tabita-Martinez, Lydia Giles | Unresectable stage III or IV melanoma  
≥ 1 measurable lesion by CT/MRI as confirmed BICR  
Must have progressed on PD-1/L1 mAb administered as monotherapy or combination (≥ 2 doses)  
Prior therapy with CTLA-4 allowed  
≥ 1 measurable disease of site by RECIST v.1.1 not previously irradiated  
Allowed for refractory pts per 3.2.4  
Treated brain mets allowed if P = 2 wks post gamma knife, surgery or stable 2 months post whole brain RT  
Stable corticosteroid dose x 1 month or tapering off and reached 20 mg prednisone or equivalent | Arm A: pembro + CTLA-4 + TIGIT  
Arm B: pembro + CTLA-4 + lenvatanib  
Phase IA: Nivo + HCQ: any prior tx or tx naive  
Phase IB: Nivo + ipi + HCQ: pts must be aPD-1 refractory  
Phase IIA: Nivo + HCQ: prior y/o in adjuvant or metastatic setting  
Phase IIB: Nivo + HCQ: pts must be aPD-1 naive, may received any other prior therapy |
| Limit for Metastatic Melanoma | UPCC 0620  | Ravi Amaravadi| CRC: Alex Mathew, CRNs: Jennifer Tabita-Martinez, Lydia Giles | Unresectable stage III or IV melanoma  
≥ 1 measurable lesion by CT/MRI as confirmed BICR  
Must have progressed on PD-1/L1 mAb administered as monotherapy or combination (≥ 2 doses)  
Prior therapy with CTLA-4 allowed  
≥ 1 measurable disease of site by RECIST v.1.1 not previously irradiated  
Allowed for refractory pts per 3.2.4  
Treated brain mets allowed if P = 2 wks post gamma knife, surgery or stable 2 months post whole brain RT  
Stable corticosteroid dose x 1 month or tapering off and reached 20 mg prednisone or equivalent | Arm A: ipi/Nivo + CTLA-4 + TIGIT  
Arm B: ipi/Nivo + CTLA-4 + lenvatanib  
Phase IA: Nivo + HCQ: any prior tx or tx naive  
Phase IB: Nivo + ipi + HCQ: pts must be aPD-1 refractory  
Phase IIA: Nivo + HCQ: prior y/o in adjuvant or metastatic setting  
Phase IIB: Nivo + HCQ: pts must be aPD-1 naive, may received any other prior therapy |
| Metastatic Trials (≥ 1 prior line) | UPCC 02921 | Justine Cohen | CRC: Joseph Vu, CRN: Lydia Rost | Has histopathologically confirmed locally advanced or metastatic solid tumor cancer (or lymphoma in Phase 1). Cancer has PD following ≥1 prior line of therapy. | Arm A: LNS8801 (PO daily)  
Arm B: LNS8801 (PO daily) + pembro (IV q21d) |